Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
Brokers' Ratings, TPs & Views on JD HEALTH After Results Ann
Recommend 42 Positive 22 Negative 38 |
||||
|
||||
|
JD HEALTH (06618.HK) once plummeted by 13.6% in early trading. It settled the midday down 9.6% at $36.9, on a turnover of over $1.9 billion. The company announced its 2024 results after the market closed yesterday (6th), in which it reported a turnover of RMB58.16 billion, up 8.6% YoY. Listed below are the latest investment ratings and target prices from four brokers as summarized by our reporters: Broker│Investment Rating│Target Price CLSA│Outperform│$40->$45 BOCI│Buy│$30->$45 HSBC Global Research│Buy->Hold│$33->$43 Goldman Sachs│Buy│$33.5 Broker│Opinion CLSA│Revenue growth accelerated but 2025 net profit may dip BOCI│2H24 profit beat with proactive investment solidifying industry-leading position HSBC Global Research│Positive outlook already reflected in stock price Goldman Sachs│2H24 sales in line, adjusted operating profit missed, and earnings outlook for 2025 conservative AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
